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Abstract
C16H16FN3OS, triclinic, P1¯ (no. 2), a= 5.6885(3) Å,
b= 9.4378(4) Å, c= 15.0736(7) Å, α= 84.037(4)°,
β= 81.442(4)°, γ = 74.271(4)°, V = 768.56(7) Å3, Z = 2,
Rgt(F)=0.0518, wRref(F2)=0.1430, T = 100 K.
CCDC no.: 1405607
The crystal structure is shown in the gure. Tables 1–3 contain
details of the measurement method and a list of the atoms
including atomic coordinates and displacement parameters.
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Table 1: Data collection and handling.
Crystal: Colourless, prism, size
0.0508×0.0622×0.4616 mm
Wavelength: CuKα radiation (1.5418 Å)
µ: 20.14 cm−1
Diractometer, scan mode: Xcalibur, Ruby, Gemini, ω scans
2θmax: 141.36°
N(hkl)measured, N(hkl)unique: 11233, 2940
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 2544
N(param)rened: 199
Programs: CrysAlis [18], SHELX [19]
Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom Site x y z Uiso
H(1) 2i 0.4381 0.6334 0.5251 0.026
H(13) 2i −0.4737 1.2318 0.8092 0.035
H(12) 2i −0.2578 1.1887 0.6676 0.030
H(6A) 2i 0.9096 0.8271 0.7583 0.030
H(6B) 2i 1.0731 0.6639 0.7605 0.030
H(16) 2i 0.3620 1.0019 0.7788 0.032
H(10A) 2i 0.3864 1.0708 0.6198 0.029
H(10B) 2i 0.1497 1.1572 0.5771 0.029
H(15) 2i 0.1479 1.0477 0.9204 0.038
H(7) 2i 0.5987 0.7620 0.8599 0.046
H(9A) 2i 0.9170 0.8135 0.9222 0.069
H(9B) 2i 1.0533 0.6451 0.9280 0.069
H(9C) 2i 0.8003 0.7030 0.9872 0.069
H(8A) 2i 0.6347 0.5257 0.8186 0.084
H(8B) 2i 0.6248 0.5259 0.9231 0.084
H(8C) 2i 0.8769 0.4663 0.8637 0.084
Source of material
4-Fluorobenzyl chloride (1.45 g, 0.01 mol) and anhydrous
potassium carbonate (1.38 g, 0.01 mol) were added to a solu-
tion of 6-(2-methylpropyl)-2-thiouracil-5-carbonitrile (2.09 g,
0.01 mol) in N,N-dimethylformamide (10 mL) and the mix-
ture was stirred at room temperature for 12 hours. Water
(15 mL) was gradually added and the mixture was stirred
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Table 3: Atomic displacement parameters (Å2).
Atom Site x y z U11 U22 U33 U12 U13 U23
S(1) 2i 0.2170(1) 0.90545(6) 0.56345(4) 0.0213(3) 0.0169(3) 0.0320(3) 0.0027(2) −0.0085(2) −0.0033(2)
O(1) 2i 0.7895(3) 0.4171(2) 0.5397(1) 0.0205(8) 0.0153(7) 0.0312(8) −0.0002(6) −0.0056(6) −0.0036(6)
N(1) 2i 0.5314(3) 0.6460(2) 0.5619(1) 0.0189(9) 0.0167(9) 0.028(1) −0.0004(7) −0.0077(7) −0.0031(7)
F(1) 2i −0.3080(3) 1.1698(2) 0.9594(1) 0.0371(9) 0.054(1) 0.0331(8) 0.0011(7) 0.0015(6) −0.0048(7)
N(2) 2i 0.5880(3) 0.8033(2) 0.6637(1) 0.0197(9) 0.0167(9) 0.029(1) −0.0010(7) −0.0038(7) −0.0022(7)
N(3) 2i 1.2865(4) 0.3801(2) 0.6700(2) 0.024(1) 0.021(1) 0.040(1) −0.0016(8) −0.0078(8) −0.0001(8)
C(5) 2i 1.1004(4) 0.4611(2) 0.6592(2) 0.023(1) 0.017(1) 0.028(1) −0.0039(9) −0.0045(9) −0.0013(8)
C(3) 2i 0.8740(4) 0.5667(2) 0.6426(2) 0.018(1) 0.017(1) 0.027(1) −0.0012(8) −0.0046(8) 0.0001(8)
C(1) 2i 0.4714(4) 0.7753(2) 0.6021(2) 0.018(1) 0.017(1) 0.027(1) −0.0022(8) −0.0014(8) −0.0015(8)
C(2) 2i 0.7375(4) 0.5334(2) 0.5781(2) 0.017(1) 0.016(1) 0.027(1) −0.0021(8) −0.0019(8) 0.0010(8)
C(4) 2i 0.7908(4) 0.6957(2) 0.6862(2) 0.019(1) 0.017(1) 0.027(1) −0.0030(8) −0.0017(8) 0.0011(8)
C(13) 2i −0.3059(4) 1.1861(3) 0.8025(2) 0.020(1) 0.024(1) 0.040(1) −0.0007(9) −0.003(1) −0.004(1)
C(12) 2i −0.1764(4) 1.1600(2) 0.7183(2) 0.023(1) 0.017(1) 0.035(1) −0.0023(9) −0.0091(9) 0.0000(9)
C(6) 2i 0.9050(4) 0.7245(2) 0.7633(2) 0.022(1) 0.018(1) 0.034(1) −0.0021(8) −0.0075(9) −0.0009(9)
C(11) 2i 0.0752(4) 1.0910(2) 0.7083(2) 0.023(1) 0.013(1) 0.033(1) −0.0029(8) −0.0049(9) −0.0024(8)
C(16) 2i 0.1945(4) 1.0486(2) 0.7849(2) 0.021(1) 0.019(1) 0.038(1) −0.0005(9) −0.0070(9) −0.0032(9)
C(14) 2i −0.1813(5) 1.1430(3) 0.8763(2) 0.031(1) 0.029(1) 0.031(1) −0.004(1) −0.000(1) −0.004(1)
C(10) 2i 0.2172(4) 1.0720(2) 0.6161(2) 0.024(1) 0.015(1) 0.033(1) −0.0007(8) −0.0059(9) −0.0002(9)
C(15) 2i 0.0678(5) 1.0750(3) 0.8694(2) 0.031(1) 0.027(1) 0.035(1) −0.001(1) −0.011(1) −0.003(1)
C(7) 2i 0.7607(5) 0.6908(3) 0.8553(2) 0.042(2) 0.042(2) 0.033(1) −0.013(1) −0.008(1) −0.001(1)
C(9) 2i 0.8953(6) 0.7153(4) 0.9301(2) 0.062(2) 0.050(2) 0.033(2) −0.023(2) −0.014(1) 0.002(1)
C(8) 2i 0.7207(7) 0.5384(4) 0.8661(2) 0.078(2) 0.060(2) 0.039(2) −0.037(2) −0.004(2) 0.002(1)
for additional 30 minutes. The precipitated crude product
was ltered, washed with water, dried, and crystallized from
aqueous ethanol to yield 2.29 g (72%) of the title compound.
M.p. 481–483 K. Colourless prismatic single crystals were
obtained by slow evaporation of an ethanolic solution at
room temperature. 1H NMR (DMSO-d6, 500.13 MHz): δ 0.92
(d, 6H, CH3, J = 6.0 Hz), 2.14 (m, 1H, CH), 2.55 (d, 2H, CH2CH,
J = 6.0 Hz), 4.46 (s, 2H, CH2S), 7.12–7.16 (m, 2H, Ar—H), 7.45–
7.47 (m, 2H, Ar—H), 13.70 (s, 1H, NH); 13C NMR (DMSO-d6,
125.76MHz): δ 22.6 (CH3), 28.0 (CH), 33.7 (CH2S), 45.4 (CH2CH),
96.2 (C-5), 115.5 (CN), 115.8, 131.4, 133.5, 162.9 (Ar—C), 161.0
(C-6), 165.9 (C=O), 174.0 (C-4); ESI-MS, m/z (rel. int.): 316.2
(M—H, 100)−.
Discussion
Various pyrimidine non-nucleoside analogues have been
developed as potent chemotherapeutic agents with anti-
cancer, antiviral, antifungal and antibacterial activities. Non-
nucleosidepyrimidine-basedanalogueshave emergedasuse-
ful therapies against human immunodeciency viruses (HIV)
[1–4], hepatitis B viruses (HBV) [5], herpes simplex viruses
(HSV) [6, 7], varicella-zoster virus (VZV) [8] and inuenza
viruses [9]. A large number of pyrimidine-based antimetabo-
lites are currently used as potent and selective anticancer
activity [10–12]. In addition, marked antibacterial and an-
tifungal activities were observed for several pyrimidine-5-
carbonitrile derivatives [13–17]. Here, we report the crystal
structure of the recently synthesized [16] title compound
(C16H16FN3OS).
The crystal structure of the title compound contains
one molecule in the asymmetric unit. With respect to the
pyrimidinyl ring, (C1/N1/C2/C3/C4/N2), the uorobenzene
ring (C11—C16) form dihedral angle of 51.2 (1)°. The molec-
ular packing is stabilized by one intermolecular hydrogen
bond where O1 acts as hydrogen bond acceptor and the NH
group (N1) is the hydrogen bond donor. The H· · ·O distance
of the N1—H1· · ·O1 hydrogen bond is 1.91(1) Å and the angle
is 169.7(1)°.
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